N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study.
Covid-19
Hospitalization
N-acetylcysteine
Journal
Caspian journal of internal medicine
ISSN: 2008-6164
Titre abrégé: Caspian J Intern Med
Pays: Iran
ID NLM: 101523876
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
02
2022
revised:
18
09
2022
accepted:
29
10
2022
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Whilst over two years have passed since the COVID-19 pandemic's emergence, the proper management of the disease remains challenging. N-acetylcysteine (NAC) as a potentially effective therapeutic option has been suggested by studies, while the exact clinical role of this agent is yet to be evaluated. This prospective case-control study was conducted in a major referral respiratory center in Tehran, Iran. We enrolled 217 patients treated with an intravenous daily dose of 1500 mg NAC as a case group; and 245 control patients who did not receive NAC. Two groups were matched based on other treatments, socio-demographics, medical history, and comorbidities. After ten days of adjuvant therapy with NAC, patients in the NAC group and control group had median room-air SpO2 of 91% and 88%, respectively (P=0.02). Also, the SpO2 to FiO2 ratio had a median of 463 and 421 in the case and control groups, respectively (P=0.01). Furthermore, the case group's hospitalization period was three days shorter (P=0.002). Further, cough, dyspnea, and decreased appetite were reported to have a significantly lower incidence in the case group (P=0.03, 0.001, 0.008). We showed that a daily intravenous dose of NAC in hospitalized COVID-19 patients could shorten the hospital stay and improve some clinical symptoms; however, it does not remarkably improve the risk of ICU admission and the 28 days in-hospital mortality rate.
Sections du résumé
Background
UNASSIGNED
Whilst over two years have passed since the COVID-19 pandemic's emergence, the proper management of the disease remains challenging. N-acetylcysteine (NAC) as a potentially effective therapeutic option has been suggested by studies, while the exact clinical role of this agent is yet to be evaluated.
Methods
UNASSIGNED
This prospective case-control study was conducted in a major referral respiratory center in Tehran, Iran. We enrolled 217 patients treated with an intravenous daily dose of 1500 mg NAC as a case group; and 245 control patients who did not receive NAC. Two groups were matched based on other treatments, socio-demographics, medical history, and comorbidities.
Results
UNASSIGNED
After ten days of adjuvant therapy with NAC, patients in the NAC group and control group had median room-air SpO2 of 91% and 88%, respectively (P=0.02). Also, the SpO2 to FiO2 ratio had a median of 463 and 421 in the case and control groups, respectively (P=0.01). Furthermore, the case group's hospitalization period was three days shorter (P=0.002). Further, cough, dyspnea, and decreased appetite were reported to have a significantly lower incidence in the case group (P=0.03, 0.001, 0.008).
Conclusion
UNASSIGNED
We showed that a daily intravenous dose of NAC in hospitalized COVID-19 patients could shorten the hospital stay and improve some clinical symptoms; however, it does not remarkably improve the risk of ICU admission and the 28 days in-hospital mortality rate.
Identifiants
pubmed: 37520878
doi: 10.22088/cjim.14.3.553
pmc: PMC10379801
doi:
Types de publication
Journal Article
Langues
eng
Pagination
543-552Déclaration de conflit d'intérêts
No conflict of interest is declared by the authors
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Ulus Travma Acil Cerrahi Derg. 2011 Jul;17(4):293-7
pubmed: 21935824
J Inflamm Res. 2021 Jul 06;14:2993-3013
pubmed: 34262324
Clin Sci (Lond). 2018 Jun 21;132(12):1257-1280
pubmed: 29967247
Radiol Cardiothorac Imaging. 2020 Mar 25;2(2):e200152
pubmed: 33778571
Int J Gen Med. 2021 Nov 23;14:8557-8571
pubmed: 34849001
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793
pubmed: 34043615
Adv Pharmacol. 2019;85:263-272
pubmed: 31307590
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Adv Pharmacol Pharm Sci. 2022 Aug 10;2022:4555490
pubmed: 35992575
Trends Pharmacol Sci. 2019 Jul;40(7):452-463
pubmed: 31147200
Sultan Qaboos Univ Med J. 2021 May;21(2):e195-e202
pubmed: 34221466
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946736
Exp Ther Med. 2017 Oct;14(4):2863-2868
pubmed: 28928799
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Medicina (Kaunas). 2020 Jul 31;56(8):
pubmed: 32752010
Clin Infect Dis. 2021 Jun 1;72(11):e736-e741
pubmed: 32964918
Front Med (Lausanne). 2021 May 14;8:670370
pubmed: 34055843
Adv Pharm Bull. 2020 Sep;10(4):488-489
pubmed: 33062600
J Clin Med. 2022 Jul 01;11(13):
pubmed: 35807123
Med Hypotheses. 2020 Oct;143:109862
pubmed: 32504923
Curr Hypertens Rep. 2020 Sep 10;22(11):90
pubmed: 32910274
World J Virol. 2021 Mar 25;10(2):34-52
pubmed: 33816149
In Vivo. 2020 Jun;34(3 Suppl):1567-1588
pubmed: 32503814
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919
pubmed: 33389262
Lancet Infect Dis. 2021 Jun;21(6):769
pubmed: 33609458
Ann Clin Biochem. 2020 Sep;57(5):339-350
pubmed: 32369402
Gastroenterology. 2009 Sep;137(3):856-64, 864.e1
pubmed: 19524577
Antioxid Redox Signal. 2021 Nov 10;35(14):1207-1225
pubmed: 33607929
Tohoku J Exp Med. 2021;255(2):127-134
pubmed: 34645738
Ther Clin Risk Manag. 2020 Nov 02;16:1047-1055
pubmed: 33177829
Shock. 2020 Nov;54(5):633-637
pubmed: 32433216
BMJ Support Palliat Care. 2021 Mar;11(1):45-52
pubmed: 32958501
Chest. 1994 Jan;105(1):190-4
pubmed: 8275731
Drug Dev Res. 2020 Aug;81(5):537-540
pubmed: 32129518
J Infect. 2022 Jan;84(1):94-118
pubmed: 34252497
Crit Care. 2020 Jul 13;24(1):422
pubmed: 32660650
Rev Esp Quimioter. 2022 Jun;35(3):236-240
pubmed: 35183067
EClinicalMedicine. 2021 May;35:100863
pubmed: 33937734